Hebei Wanbang Fulin Pharmaceutical Co., Ltd. is controlled by Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. The company's registered capital reaches 62.0438 million yuan, covering an area of ??67,000 square meters, a construction area of ??21,000 square meters, and 187 employees. The company has traditional Chinese medicine extraction and pre-treatment workshops and two preparation workshops, which can produce hard capsules, tablets, pills, granules and other dosage forms. The company has passed the national GMP certification.
Since its establishment, the company has been awarded the honorary titles of Hebei Star Enterprise, Hebei Excellent Enterprise, and Hebei Harmonious Labor Relations Enterprise. The Xingquan brand is a famous trademark in Hebei Province. In 2005, the company was awarded the "2005 AAA Credit Customer" by the Hebei Branch of the Agricultural Bank of China.
The company's leading product, compound aloe vera capsules, is a pure traditional Chinese medicine compound preparation successfully developed by the company in 1985. It is a national second-class protected traditional Chinese medicine variety and is exclusively produced in China. It uses natural aloe vera imported from Africa as the main raw material, which has the effects of clearing the liver and purging heat, moistening the intestines and laxative, and calming the mind and calming the mind. Used for excessive heart and liver fire, constipation, abdominal distension and pain, irritability and insomnia. This product has the characteristics of accurate curative effect, mild action, quick onset, good stability, few adverse reactions, low dosage, convenient taking, and low price. It has been put on the market for more than 20 years and has been widely welcomed by patients and doctors. It has a high market coverage and enjoys a high reputation among laxative drugs nationwide. In 2009, relying on the powerful Wanbang Pharmaceutical platform, the company's sales performance reached a new high.
The company adheres to the people-oriented approach, strengthens team building, focuses on introducing professional and technical talents, and implements product innovation and patent development in accordance with the company's corporate positioning of "leader in traditional Chinese medicine laxative products" and "innovator in traditional Chinese medicine hypoglycemic products" Strategy, carry out in-depth development of compound aloe vera capsules, innovatively develop a series of traditional Chinese medicine blood sugar-lowering products, establish the company's competitive advantages in the direction of constipation, traditional Chinese medicine blood sugar-lowering and other products, and strive to become a well-known enterprise in the field of traditional Chinese medicine laxative and blood sugar-lowering. Shanghai Kaimao Biopharmaceutical Co., Ltd. was established on November 19, 2008, with a registered capital of RMB 105 million. It was jointly established by Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. and Spanish CHEMO Group. Spain's Chemo Group is a company integrating R&D, production and sales of chemicals, pharmaceuticals and biomedicines. It has its own R&D bases, production companies and business networks around the world. Committed to the research, development, production and commercialization of pharmaceutical products worldwide, its purpose is to provide high-quality products through continuous technological innovation and apply it to product research and development, and to unremitting efforts to achieve human health. struggle.
The company is located in Caohejing High-tech Industrial Park, Xuhui District, Shanghai. The factory covers an area of ??30 acres. It has 3 genetic engineering product workshops and 2 freeze-dried powder injection preparation workshops, and has advanced production technology. and equipment. The company's main features are biotechnology drugs and anti-tumor drugs. The establishment of the joint venture is an important step in the internationalization of the pharmaceutical business.
Kaimao Biotech has more than 10 years of experience in R&D, production and operation: it has the core resources of the corporate technology center of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; it has the nationwide marketing of Jiangsu Wanbang Pharmaceutical Network and production quality R&D resources; it has the global sales network and biotechnology R&D resources of the Spanish CHEMO Group.
The company's main products include: National Class II new drug - Clone Gamma (recombinant interferon gamma for injection), Clone Yibao (recombinant human erythropoietin for injection), National Class I new drug - Si Kaitong (recombinant streptokinase for injection), and Yiluoze (pemetrexed disodium for injection), an important result of research and development in the new anti-tumor field in recent years. The company will continue to conduct research and development of new drugs in the field of tumor treatment, focusing on the innovation, effectiveness and safety of drugs, and strive to develop a batch of new drugs with independent intellectual property rights and market competitiveness. At the same time, we actively organize and promote the competitiveness of existing products in the international market. We have obtained registration certificates from many countries such as South America, Eastern Europe, and Southeast Asia.
Shanghai Zhaohui Pharmaceutical Co., Ltd.
Shanghai Zhaohui Pharmaceutical Co., Ltd. was formerly known as the Second Military Medical University Zhaohui Pharmaceutical Factory and was founded in 1958. At the end of 1998, according to the unified deployment of the Central Military Commission, it was transferred to the local government of Baoshan District for management.
In early 1999, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (formerly Shanghai Fosun Industrial Co., Ltd.) participated in corporate operations and established Shanghai Fosun Zhaohui Pharmaceutical Co., Ltd. with a registered capital of 10 million yuan. In December 2005, the registered capital of the company increased to RMB 100 million. In July 2007, due to the need to create its own brand and establish its own brand image, the company changed its name to Shanghai Zhaohui Pharmaceutical Co., Ltd. Since December 2008, it has been under the management of Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
The new factory of Shanghai Zhaohui Pharmaceutical Co., Ltd., built with an investment of 140 million yuan, is located in Luodian Industrial Park, Baoshan District, Shanghai, and was officially opened at the end of 2002. The company covers an area of ??100 acres, with a building area of ??11,026 square meters, a total construction area of ??20,465 square meters, a green area of ??28,445 square meters, and a greening rate of 44.5%.
In January 2003, tablets, capsules (all containing anti-tumor drugs), granules, ointments (hormones), small-volume injections and APIs (hydrochloric acid) of Shanghai Zhaohui Pharmaceutical Co., Ltd. Lidocaine) and other eight production lines successfully passed the on-site GMP verification of the State Food and Drug Administration at one time and obtained GMP certificates. In May 2003, the company's ointments (non-hormonal) also passed GMP certification. In December 2007, the company passed the GMP review by the State Food and Drug Administration and Shanghai Food and Drug Administration.
The API varieties Bemeg and Acetyl Glutamide obtained GMP certificates in May 2009; the API calcium dobesilate obtained the GMP certificate in July 2009; the API perphenazine obtained the GMP certificate in 2011 Obtained GMP certificate in March.
The company's main products involve endocrinology, anti-tumor, dermatology, analgesia and other fields. Among the new drugs in the "Ke" series, "Keyou" penciclovir cream, "Keyi" exemestane tablets, "Kefu" deoxyfluridine capsules, "Keyi" meloxicam tablets, "Keyi" Products such as "Yuan" calcium dobesilate capsules and "CaCheng" pioglitazone hydrochloride tablets have been selected into Shanghai's high-tech transformation projects and have entered the national medical insurance Category A and B catalog.